The acetylation state of histone is reversibly regulated by histone acetyltransferase (HAT)
and deacetylase (HDAC). An imbalance of this reaction leads to an aberrant behavior of the …

Histone deacetylase inhibitors (HDI) are a promising new approach to the treatment of
cancer. HDIs have been shown to induce differentiation, cell cycle arrest, and apoptosis in a …

New therapies are required for chronic lymphocytic leukemia (CLL), an incurable disease
characterized by failure of mature lymphocytes to undergo apoptosis. Activation of cell …

Purpose: We have synthesized a series of hybrid polar compounds that induce
differentiation and/or apoptosis of various transformed cells. These agents are also potent …

Histone deacetylase inhibitors show promise as chemotherapeutic agents and have been
demonstrated to block proliferation in a wide range of tumor cell lines. Much of this …

We have synthesized a histone deacetylase inhibitor, NVP-LAQ824, a cinnamic hydroxamic
acid, that inhibited in vitro enzymatic activities and transcriptionally activated the p21 …

A new class of colchicine derivatives were designed and synthesized as tubulin–HDAC dual
inhibitors. Biological evaluations of these hybrids included the inhibitory activity of HDAC …

From work done largely on derived cell lines, it has been suggested that tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL) might be a therapeutic target for many …

Several histone deacetylase inhibitors (HDACi), which have recently entered early clinical
trials, exert their anticancer activity in part through the induction of apoptosis although the …

Histone deacetylase (HDAC) and histone acetyltransferase (HAT) functions are associated
with various cancers, and the inhibition of HDAC has been found to arrest disease …